SG Americas Securities Boosts Stake in CG Oncology

Institutional investor increases holdings in biotech firm by nearly 93%

Apr. 10, 2026 at 8:53am

Got story updates? Submit your updates here. ›

An extreme close-up of various gears, levers, and other industrial components that make up the inner workings of a banking or financial institution, conveying a sense of the complex, unseen infrastructure that underpins the modern economy.The heavy, tangible machinery and mechanisms that power the financial industry remain largely hidden from public view, but represent the backbone of modern wealth and economic security.South San Francisco Today

SG Americas Securities LLC, an institutional investor, has increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 92.7% in the fourth quarter, according to a recent regulatory filing. The firm now owns 20,949 shares of the biopharmaceutical company's stock, valued at $870,000.

Why it matters

CG Oncology is a clinical-stage biotech company focused on developing novel antibody-based immunotherapies for solid tumor cancers. The increase in institutional investment suggests growing confidence in the company's pipeline and future prospects.

The details

SG Americas Securities purchased an additional 10,077 shares of CG Oncology in the fourth quarter, bringing its total holdings to 20,949 shares. This represents a 92.7% increase in the firm's stake in the company. Several other major institutional investors, including Wellington Management Group, Bank of America, and Vanguard, have also significantly increased their positions in CG Oncology over the past year.

  • SG Americas Securities reported the increased stake in a regulatory filing on April 10, 2026.
  • The purchases were made during the fourth quarter of 2025.

The players

SG Americas Securities LLC

An institutional investment firm that has increased its stake in CG Oncology, Inc.

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from SG Americas Securities and other major institutional investors suggests growing confidence in CG Oncology's ability to advance its pipeline of cancer immunotherapies and deliver value for shareholders.